Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia.
acute myeloid leukemia
cancer stem cell
colony forming unit
leukemic progenitor cell
leukemic stem cell
prognostic
survival
xenotransplantation
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
18 07 2023
18 07 2023
Historique:
received:
12
08
2022
revised:
29
01
2023
accepted:
16
06
2023
medline:
21
7
2023
pubmed:
12
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
We systematically investigate functional and molecular measures of stemness in patients with acute myeloid leukemia (AML) using a cohort of 121 individuals. We confirm that the presence of leukemic stem cells (LSCs) detected through in vivo xenograft transplantation is associated with poor survival. However, the measurement of leukemic progenitor cells (LPCs) through in vitro colony-forming assays provides an even stronger predictor of overall and event-free survival. LPCs not only capture patient-specific mutations but also retain serial re-plating ability, demonstrating their biological relevance. Notably, LPC content represents an independent prognostic factor in multivariate analyses including clinical guidelines of risk stratification. Our findings suggest that LPCs provide a robust functional measure of AML, enabling quantitative and rapid assessment of a wide range of patients. This highlights the potential of LPCs as a valuable prognostic factor in AML management.
Identifiants
pubmed: 37433297
pii: S2666-3791(23)00236-7
doi: 10.1016/j.xcrm.2023.101108
pmc: PMC10394166
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101108Informations de copyright
Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
J Exp Med. 2016 Jul 25;213(8):1513-35
pubmed: 27377587
Blood. 2010 Mar 11;115(10):1976-84
pubmed: 20053758
Cancer Cell. 2018 Sep 10;34(3):483-498.e5
pubmed: 30205048
Stem Cells. 2017 Sep;35(9):2095-2102
pubmed: 28758276
Nature. 2014 Oct 16;514(7522):322-7
pubmed: 25296256
Blood. 2006 Feb 1;107(3):1166-73
pubmed: 16234360
Exp Hematol. 2018 Mar;59:66-71.e4
pubmed: 29253573
Cell Rep Med. 2021 Feb 16;2(2):100202
pubmed: 33665638
Clin Cancer Res. 2005 Sep 15;11(18):6520-7
pubmed: 16166428
Nature. 2014 Feb 20;506(7488):328-33
pubmed: 24522528
Nature. 1994 Feb 17;367(6464):645-8
pubmed: 7509044
Genome Biol. 2016 Apr 27;17:75
pubmed: 27122128
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Blood Cancer J. 2022 Aug 16;12(8):117
pubmed: 35973983
PLoS One. 2014 Sep 22;9(9):e107587
pubmed: 25244440
Blood. 2022 Sep 22;140(12):1345-1377
pubmed: 35797463
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Blood. 1998 Dec 1;92(11):4325-35
pubmed: 9834239
Haematologica. 2018 Jun;103(6):959-971
pubmed: 29545344
Blood. 2020 Jan 30;135(5):371-380
pubmed: 31826241
J Clin Oncol. 1989 Jun;7(6):738-46
pubmed: 2715804
Nat Med. 2022 Jun;28(6):1212-1223
pubmed: 35618837
Cell Stem Cell. 2019 Jan 3;24(1):41-53
pubmed: 30609398
Nature. 2017 Jul 6;547(7661):104-108
pubmed: 28658204
Blood. 1996 Jun 1;87(11):4754-61
pubmed: 8639846
Blood. 1982 Mar;59(3):601-8
pubmed: 6949614
Nat Med. 2011 Aug 28;17(9):1086-93
pubmed: 21873988
Nat Med. 1997 Jul;3(7):730-7
pubmed: 9212098
Br J Haematol. 2001 Aug;114(2):296-306
pubmed: 11529847
Blood. 2016 Apr 21;127(16):2018-27
pubmed: 26834243
Leukemia. 2006 Dec;20(12):2147-54
pubmed: 17039238
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Blood Adv. 2022 Feb 8;6(3):1064-1073
pubmed: 34872104
Stem Cells. 2006 Mar;24(3):631-41
pubmed: 16210406
J Clin Oncol. 1984 Apr;2(4):253-9
pubmed: 6368758
Leukemia. 2012 Apr;26(4):858-60
pubmed: 21926966
Nature. 2016 Dec 15;540(7633):433-437
pubmed: 27926740
J Clin Invest. 2011 Jan;121(1):384-95
pubmed: 21157036